Intranasal respiratory syncytial virus vaccine - Virtuvax
Alternative Names: Respiratory Syncytial Virus vaccine - Virtuvax; SynGEM; SynGEM prefusion F vaccine - VirtuvaxLatest Information Update: 10 Apr 2025
At a glance
- Originator Imperial College of Science, Technology and Medicine; Mucosis
- Class Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 06 Mar 2019 Adverse events data from a phase I trial in Respiratory syncytial virus infections released by Virtuvax
- 13 Feb 2019 Immunogenicity and adverse events data from a phase I trial in Respiratory syncytial virus infections (In volunteers) released by Virtuvax
- 01 Oct 2016 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in United Kingdom (Intranasal) (NCT02958540)